Medigen links up with Charles River in push to take enterovirus vaccine global

Charles River Laboratories (CRL) and Taiwan-based Medigen Vaccine Biologics are teaming up to prep Medigen’s multivalent enterovirus vaccine for global expansion.
The collaboration is designed to characterize and validate the virus seed bank for Medigen’s vaccine and will leverage CRL’s analytical platforms, according to a Thursday release.
CRL’s Next-Generation Sequencing will support the chemistry, manufacturing and controls steps to advance the vaccine program, including Medigen’s Envacgen enterovirus 71 vaccine, which has already been approved in Taiwan and Vietnam. The contagious virus is the leading cause of hand, foot and mouth disease and usually affects infants and young children. It can also lead to severe brain and nerve problems.
“We are excited to collaborate with MVC and apply our testing and NGS expertise for vaccine development,” said Kerstin Dolph, CRL’s corporate senior vice president of global manufacturing in a release. “By leveraging our experience in biologics, analytics, and safety, we are proud to partner with companies like MVC to achieve key milestones and drive innovation in the industry.”
CRL’s new CEO, Birgit Girshick, spoke with Fierce earlier this summer about the increasing importance of CRO collaboration with trial sponsors.
The company will deploy its biologics testing and non-clinical development capabilities, while Medigen’s vaccine research expertise will help build the data needed for global regulatory readiness and support IND applications and future global clinical development. Beyond enterovirus, the companies will look for additional opportunities in other vaccine programs.
“The success of a new vaccine relies not only on innovative technology but also on establishing development strategies that meet global regulatory and scientific standards from the very beginning,” Leo Lee, CEO of Medigen, said in a statement. “We are pleased to collaborate strategically with Charles River and leverage its expertise in NGS and biologics testing to establish a high-quality vaccine development process aligned with international regulatory expectations.”
Founded in 2012, Medigen has focused on vaccines and infectious diseases and received emergency use authorization in Taiwan during the COVID-19 pandemic.

Facts Only

* Charles River Laboratories (CRL) and Medigen Vaccine Biologics are teaming up.
* The collaboration aims to characterize and validate the virus seed bank for Medigen’s multivalent enterovirus vaccine for global expansion.
* The collaboration will leverage CRL’s analytical platforms.
* CRL’s Next-Generation Sequencing (NGS) will support chemistry, manufacturing, and controls steps.
* This support includes advancing Medigen’s Envacgen enterovirus 71 vaccine.
* The enterovirus 71 vaccine is already approved in Taiwan and Vietnam.
* Enterovirus is the leading cause of hand, foot, and mouth disease, often affecting infants and young children and potentially causing severe brain and nerve problems.
* CRL will deploy biologics testing and non-clinical development capabilities.
* Medigen’s vaccine research expertise will help build data for global regulatory readiness and support IND applications.
* The companies will look for additional opportunities in other vaccine programs.

Executive Summary

Charles River Laboratories (CRL) and Taiwan-based Medigen Vaccine Biologics are collaborating to prepare Medigen’s multivalent enterovirus vaccine for global expansion. The partnership involves characterizing and validating the virus seed bank for the vaccine using CRL’s analytical platforms. Next-Generation Sequencing (NGS) from CRL will support the chemistry, manufacturing, and controls steps for advancing the vaccine program, including Medigen’s Envacgen enterovirus 71 vaccine, which is approved in Taiwan and Vietnam. Kerstin Dolph of CRL stated excitement about applying their testing and NGS expertise to vaccine development by leveraging their experience in biologics, analytics, and safety.
Medigen will contribute its vaccine research expertise to build the necessary data for global regulatory readiness and support Investigational New Drug (IND) applications and future clinical development. Leo Lee, CEO of Medigen, emphasized that success requires establishing development strategies aligned with global regulatory and scientific standards from the outset, emphasizing the strategic collaboration with Charles River's NGS and biologics testing expertise. Beyond enterovirus, the companies intend to pursue opportunities in other vaccine programs.

Full Take

The collaboration illustrates a pattern where specialized analytical services (NGS, biologics testing) are strategically integrated into the early stages of vaccine development to meet complex global regulatory demands. The structure suggests that achieving global readiness—which requires meeting diverse international scientific and regulatory standards—is seen as contingent on leveraging external, high-level expertise rather than relying solely on internal capabilities. This pattern implies a systemic understanding that innovation must be built upon a foundation of validated, globally acceptable data infrastructure from the start. The interplay between CRL’s technical execution and Medigen’s biological knowledge highlights a necessary bridge between laboratory science and regulatory reality. The implication is that for complex public health products like vaccines to achieve global viability, external validation mechanisms must be prioritized alongside internal research streams. What assumptions underpin the necessity of this specific partnership over purely in-house methods? What are the long-term implications if global expansion necessitates relying heavily on externally validated NGS platforms?